The global healthcare industry is experiencing rapid transformation as the rising prevalence of type 2 diabetes, chronic kidney disease (CKD), and cardiovascular disorders drives demand for advanced glucose-lowering therapies. According to Future Market Insights (FMI), the Dapagliflozin Market is projected to surge from USD 267.96 million in 2026 to USD 4,584.38 million by 2036, registering an...